Cytek Biosciences Inc Capital Reinvestment Ratio
Cytek Biosciences Inc capital reinvestment ratio. Cytek Biosciences Inc (CTKB) has a Capital Reinvestment Ratio of 14.60x as of June 2025, meaning it reinvests 15% of its operating cash flow ($108.00K) in capital expenditures ($1.58 Million). Check CTKB capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Cytek Biosciences Inc (2020–2024)
Capital reinvestment ratio of Cytek Biosciences Inc from 2020 to 2024. This chart tracks Cytek Biosciences Inc's Capital Reinvestment Ratio across 4 annual periods. Also explore CTKB net assets growth trend to track the company's year-over-year net asset growth rate.
Cytek Biosciences Inc Capital Reinvestment Ratio by Year (2020–2024)
Cytek Biosciences Inc capital reinvestment ratio by year from 2020 to 2024. For the full cash flow conversion analysis, see Cytek Biosciences Inc (CTKB) cash conversion ratio.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.14x | $25.38 Million | $3.52 Million | ▼ -84.8% |
| 2023 | 0.91x | $5.28 Million | $4.83 Million | ▼ -3.0% |
| 2021 | 0.94x | $4.63 Million | $4.36 Million | ▲ +823.4% |
| 2020 | 0.10x | $15.16 Million | $1.55 Million | — |